Data Insights
No Filter Selected
No Filter Selected
No Filter Selected
No Filter Selected
Adebrelimab by Jiangsu Hengrui Medicine for Nasopharyngeal Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Nasopharyngeal Cancer. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Bile Duct Cancer (Cholangiocarcinoma): Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Bile Duct Cancer (Cholangiocarcinoma). According...
Adebrelimab by Jiangsu Hengrui Medicine for Small-Cell Lung Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Small-Cell Lung Cancer. According to...
Adebrelimab by Jiangsu Hengrui Medicine for Hepatocellular Carcinoma: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Hepatocellular Carcinoma. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Esophageal Squamous Cell Carcinoma (ESCC): Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Esophageal Squamous Cell Carcinoma (ESCC)....
Adebrelimab by Jiangsu Hengrui Medicine for Pancreatic Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Pancreatic Cancer. According to GlobalData,...
Adebrelimab by Jiangsu Hengrui Medicine for Metastatic Pancreatic Cancer: Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase II for Metastatic Pancreatic Cancer. According to...
Adebrelimab by Jiangsu Hengrui Medicine for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval
Adebrelimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase I for Head And Neck Squamous Cell...